INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• Bio/Pharmaceutical Facility Validation And Environmental Monitoring

  Gain insight into how experienced validation and monitoring partners help organizations establish compliant operations, maintain facility performance, manage risk, and support long-term operational excellence.

• Viral Safety Testing In Biologics: Detecting What Current Methods Miss

  Biologics face unpredictable risks as complexity grows; evolving testing strategies to broaden detection, address gaps, and strengthen safety confidence without disrupting development or compliance.

• Science With Purpose: Advancing Sustainability In Biopharma Testing

  Learn how biopharma labs are cutting animal use, energy, and paper waste while maintaining GMP compliance — with specific data on 85% labor reductions and 1 ton of CO2e saved annually.

• Plant-Based Peptones For Bioprocessing

  Plant-based, animal-free peptones enhance bioprocessing by improving yields, supporting low-serum conditions, simplifying media design, and enabling consistent and compliant cell culture performance.

• Strategic Use Of Yeast Extracts In Cell Culture

  Animal-free yeast extracts enhance cell culture and fermentation by improving yields, cell health, and consistency, while supporting regulatory confidence, supply security, and media performance.

• Peptones, Hydrolysates, And Yeast Extracts

  We offer plant-based, animal-free peptones, hydrolysates, and yeast extracts in ultrafiltered and microfiltered formats, supporting cell culture, fermentation performance, and bioprocess nutrition.

• 100% Animal-Free Production And Control

  See animal-free peptones and hydrolysates enabling consistent, scalable cell culture and fermentation, with variability reduction, regulatory support, and customizable manufacturing solutions.

• GPEx® Lightning: Stable Cell Line Development For Complex Biologics

  GPEx® Lightning delivers stable cell pools in 25 days, titers exceeding 15g/L for mAbs and 11g/L for bispecifics, and 60+ generations of stability — compressing timelines by 6–12 weeks.

• AAV Production Technology For Scalable, High-Quality Manufacturing

  Plasmid-free AAV production technology enhances yield, purity, and scalability, enabling cost-efficient manufacturing, reduced variability, and consistent high-quality vectors for gene therapy.

• Lentiviral Packaging & Producer Cell Lines For LVV Manufacturing

  Stable lentiviral vector line platforms enable scalable, cost-efficient manufacturing by reducing plasmids, simplifying processes, improving consistency, and supporting volume production.